Skip to content
Open access

Frequency of Clinically Relevant Drug–Drug Interactions Between Tyrosine Kinase Inhibitors and Proton Pump Inhibitors in Patients With Cancer Using Real‐World Data

Oct 2026 · Basic & Clinical Pharmacology & Toxicology · Vol 139 · 0 citations · 30 references
Medicine

Abstract

Proton pump inhibitors (PPIs) raise stomach pH, leading to reduced bioavailability of many tyrosine kinase inhibitors (TKIs), thereby affecting treatment outcomes. To what extent this interaction occurs in clinical practice remains underexplored.

Read PDF

Similar papers

Review Open access Oct 2026

Safety Profiles of Immune Checkpoint Inhibitor Strategies in Gastrointestinal Cancers and Their Association With Clinical Outcomes: A Systematic Review and Meta‐Analysis

Immune checkpoint inhibitors (ICIs) are increasingly used in patients with gastrointestinal cancer (GIC). However, ICI‐associated adverse event (AE) profiles in GIC remain poorly characterized, and whether AE incidence is associated with clinical outcomes is unclear.

Jing Lei, Yi-Yi Yu, Qing Liu et al. · 1 citation
Review Open access Oct 2026

STRUCTURE–ACTIVITY RELATIONSHIPS AND FUTURE PROSPECTS OF IMATINIB AND NILOTINIB DERIVATIVES IN BCR::ABL1 TYROSINE KINASE INHIBITION

Materials and methods. A literature review was conducted based on scientific publications investigating imatinib and nilotinib derivatives. Structural modification strategies, including aromatic and heterocyclic fragment modification, halogen and trifluoromethyl (CF₃) substitution, sp³-rich fragment introduction, hybri...

M. Mamajonova · 0 citations
Editorial Open access Oct 2026

Editorial: Mechanisms of drug resistance in cancer: overcoming barriers with novel pharmacological strategies

the importance of clinicopathological characterization and biomarker discovery. Emerging pharmacological approaches, including EZH2 inhibition, PARP-directed combination therapies, and natural product-based therapies such as (+)-PTC, may restore therapeutic sensitivity and ultimately contribute to precision oncology an...

Pulak Kar, D. Colangelo, M. Kumar et al. · 0 citations
Open access Oct 2026

Comparative Efficacy and Safety of Bruton Tyrosine Kinase and Spleen Tyrosine Kinase Inhibitors in Immune Thrombocytopenia: A Network Meta‐Analysis of Clinical Trials

Targeted kinase inhibitors have shown statistically and clinically significant improvements in platelet response among patients with primary ITP, supporting their utility as effective targeted therapeutic strategies. We evaluated the efficacy and safety of Bruton tyrosine kinase (BTK) and spleen tyrosine kinase (SYK) i...

Ayah Abulehia, R. B. Alshareef, Shorouq Khateeb et al. · 0 citations
Review Open access Sep 2026

Efficacy and Safety of PD‐1/PD‐L1 Inhibitors Combined With Anti‐Angiogenic Tyrosine Kinase Inhibitors for Recurrent or Metastatic Nasopharyngeal Carcinoma: A Systematic Review and Single‐Arm Meta‐Analysis

To evaluate the efficacy and safety of PD‐1/PD‐L1 inhibitors plus small‐molecule anti‐angiogenic drugs (apatinib, anlotinib and famitinib) for recurrent/metastatic nasopharyngeal carcinoma (R/M NPC).

Rong-Yi Hu, Tie-Bin Li, Zi-Man Luo et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.